Potent inhibitor of leucine-rich repeat kinase 2 (LRRK2) (IC50
values are 1.28 nM and 1.85 nM for wild-type and G2019S mutant forms of LRRK2 respectively). Attenuates neuronal injury induced by LRRK2-G2019S mutant activity in primary human neurons (EC50
= 1 nM).
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons.
Ramsden et al.
ACS Chem.Biol., 2011;6:1021
Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models.
Kramer et al.
ACS Chem.Neurosci., 2012;3:151